Recombinant Mouse ZNRF3 Fc Chimera Protein, CF

Catalog #: 8328-RF Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
8328-RF-050

2 Images

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Mouse ZNRF3 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE with silver staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Mouse R‑Spondin 3 (Catalog # 4120-RS) is coated at 0.25 µg/ml, Recombinant Mouse ZNRF3 Fc Chimera binds with an apparent K_d <0.2 nM.

Source

Mouse myeloma cell line, NS0-derived mouse ZNRF3 protein

Mouse ZNRF3 (Lys53-Met216) Accession # Q5SSZ7	IEGRMDP	Mouse IgG_2a (Glu98-Lys330)
N-terminus		C-terminus

Accession #

Q5SSZ7

N-terminal Sequence
Analysis

Lys53

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

45 kDa

SDS-PAGE

51-60 kDa, reducing conditions

Product Datasheets

8328-RF

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

8328-RF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

When Recombinant Mouse R-Spondin 3 (Catalog # 4120-RS) is coated onto a microplate well at 0.25 µg/mL, Recombinant Mouse ZNRF3 Fc Chimera (Catalog # 8328-RF) binds with an apparent K_d<0.2 nM.

SDS-PAGE

View Larger

1 μg/lane of Recombinant Mouse ZNRF3(Catalog # 8328-RF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing bands at 54.7 and 138 kDa, respectively.

Reconstitution Calculator

Background: ZNRF3

ZNRF3 (zinc/RING finger protein 3) is a member of the ZNRF3 family of type 1 transmembrane ubiquitin ligases (1). Mature mouse ZNRF3 consists of a 163 amino acid (aa) extracellular domain (ECD) with a protease associated (PA) domain fold, a short transmembrane segment, and a 675 aa cytoplasmic tail that contains a RING-type zinc finger with E3 ubiquitin ligase activity. Within the ECD, mouse and human ZNRF3 share 98% sequence identity. ZNRF3 is co-expressed on the cell surface with the homologous protein RNF43. Both proteins serve to inhibit the Wnt signaling pathway through the ubiquitination of LRP6 and a majority of the Frizzled family of Wnt receptors (1, 4, 6). ZNRF3 ubiquitin ligase activity is regulated jointly by R-Spondin and its cell surface receptors, Lgr4, 5, and 6 (2). The R-Spondin-Lgr complex binds to and facilitates the removal of the ZNRF3 from the plasma membrane, resulting in an enhancement of Wnt signaling (3, 4). Conversely, ZNRF3 can antagonize R-Spondin enhanced Wnt signaling (3, 5). ZNRF3 is highly expressed in crypt stem cells of the intestine where it modulates Wnt-induced cell proliferation to control the turnover of intestinal epithelial cells (6). ZNRF3 expression is down-regulated in gastric carcinomas, and ZNRF3 mutations are linked to carcinomas of the gastric tract, pancreas, liver, and ovary (7-10).

References